ALLMedicine™ Biliary Tract Cancer Center
Research & Reviews 582 results
https://doi.org/10.1080/01635581.2022.2074063
Nutrition and Cancer; Yang L, He Y et. al.
May 12th, 2022 - The purpose of this meta-analysis was to analyze the influences of sarcopenia on clinical outcomes in patients with biliary tract cancer (BTC). A systematic literature search was performed in November 2021. Some studies that reported the impacts o...
https://clinicaltrials.gov/ct2/show/NCT04482309
May 11th, 2022 - This is an open-label, multi-center, multi-cohort, Phase 2 study to evaluate the efficacy and safety of trastuzumab deruxtecan (T-DXd) for the treatment of selected HER2-expressing tumors. This study will enroll 7 tumor-specific cohorts: urothelia...
https://clinicaltrials.gov/ct2/show/NCT03929666
May 11th, 2022 - Part 1 of the study will first evaluate the safety and tolerability of ZW25 plus standard first-line combination chemotherapy (XELOX, FP, or mFOLFOX6 for GEA; mFOLFOX6 with or without bevacizumab for CRC; and CisGem for BTC) and will confirm the r...
https://clinicaltrials.gov/ct2/show/NCT04579380
May 10th, 2022 - There are multiple cohorts in this trial: 5 tumor specific cohorts with HER2 overexpression/amplification (cervical cancer, uterine cancer, biliary tract cancer, urothelial cancer, and non-squamous non-small cell lung cancer [NSCLC]) 2 tumor speci...
https://clinicaltrials.gov/ct2/show/NCT04042831
May 9th, 2022 - PRIMARY OBJECTIVES: I. To determine the efficacy (objective response rate) of olaparib monotherapy in advanced biliary tract cancer (BTC) with mutations in deoxyribonucleic acid (DNA) repair genes. SECONDARY OBJECTIVES: I. To determine the overall...
Guidelines 2 results
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8058005
Clinical & Translational Oncology : Official Publication ... Gómez-España MA, Montes AF et. al.
Mar 5th, 2021 - Pancreatic cancer (PC) and biliary tract cancer (BTC) are both aggressive and highly fatal malignancies. Nowadays we have a profound knowledge about the molecular landscape of these neoplasms and this has allowed new therapeutic options. Surgery i...
https://doi.org/10.1200/JCO.18.02178
Journal of Clinical Oncology : Official Journal of the Am... Shroff RT, Kennedy EB et. al.
Mar 12th, 2019 - To develop an evidence-based clinical practice guideline to assist in clinical decision making for patients with resected biliary tract cancer. ASCO convened an Expert Panel to conduct a systematic review of the literature on adjuvant therapy for ...
Clinicaltrials.gov 62 results
https://clinicaltrials.gov/ct2/show/NCT04482309
May 11th, 2022 - This is an open-label, multi-center, multi-cohort, Phase 2 study to evaluate the efficacy and safety of trastuzumab deruxtecan (T-DXd) for the treatment of selected HER2-expressing tumors. This study will enroll 7 tumor-specific cohorts: urothelia...
https://clinicaltrials.gov/ct2/show/NCT03929666
May 11th, 2022 - Part 1 of the study will first evaluate the safety and tolerability of ZW25 plus standard first-line combination chemotherapy (XELOX, FP, or mFOLFOX6 for GEA; mFOLFOX6 with or without bevacizumab for CRC; and CisGem for BTC) and will confirm the r...
https://clinicaltrials.gov/ct2/show/NCT04579380
May 10th, 2022 - There are multiple cohorts in this trial: 5 tumor specific cohorts with HER2 overexpression/amplification (cervical cancer, uterine cancer, biliary tract cancer, urothelial cancer, and non-squamous non-small cell lung cancer [NSCLC]) 2 tumor speci...
https://clinicaltrials.gov/ct2/show/NCT04042831
May 9th, 2022 - PRIMARY OBJECTIVES: I. To determine the efficacy (objective response rate) of olaparib monotherapy in advanced biliary tract cancer (BTC) with mutations in deoxyribonucleic acid (DNA) repair genes. SECONDARY OBJECTIVES: I. To determine the overall...
https://clinicaltrials.gov/ct2/show/NCT05109442
May 3rd, 2022 - There will be 2 parts in this study: a dose escalation phase (phase 1) and an expansion phase (phase 2a). Patients will qualify to receive the investigational drugs (AFM24 + atezolizumab) in the dose escalation phase or the expansion phase only if...
News 61 results
https://www.onclive.com/view/targeted-combo-notches-rare-success-in-glioblastoma
Mar 30th, 2022 - For more than 20 years, investigators have tried numerous targeted therapy strategies against glioblastoma (GBM) that have fallen frustratingly short in establishing clinical benefit.1 That changed in November 2021 when an international team of in...
https://www.medpagetoday.com/hematologyoncology/othercancers/97627
Mar 11th, 2022 - Legislation introduced by Rep. Frank Pallone (D-N.J.) would give the FDA authority to set an expiration date on accelerated approvals. (Regulatory Affairs Professionals Society) Immune checkpoint inhibitors developed in China will have to overcome...
https://www.onclive.com/view/phase-3-nutide-121-study-examining-nuc-1031-in-biliary-tract-cancer-to-be-discontinued
Mar 8th, 2022 - The phase 3 NuTide:121 trial (NCT04163900) examining the first-in-class nucleotide analogue NUC-1031 (Acelarin) in combination with cisplatin vs gemcitabine plus cisplatin in patients with advanced biliary tract cancer is being discontinued, accor...
https://www.onclive.com/view/sequencing-strategies-may-shift-with-emerging-options-in-gi-malignancies
Feb 11th, 2022 - With the rapid uptake oof novel therapies, shifts in treatment strategies are anticipated in gastrointestinal (GI) malignancies, including hepatobiliary cancers, locally advanced and metastatic pancreatic cancer, gastric/gastroesophageal junction ...
https://www.medscape.com/viewarticle/967102
Jan 24th, 2022 - SAN FRANCISCO ― Adding the checkpoint inhibitor durvalumab (Imfinzi) to chemotherapy significantly improved overall survival in patients with advanced biliary tract cancer, as compared to chemotherapy alone, according to interim results from the T...
